Corvus Pharmaceuticals, Inc.

( )
CRVS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -1.67%137.430.7%$2196.88m
PFEPfizer Inc. -2.81%33.600.9%$1393.77m
MRKMerck & Co., Inc. -2.23%78.520.7%$1292.94m
ABBVAbbVie, Inc. -0.59%75.282.3%$1206.98m
BMYBristol-Myers Squibb Co. -1.71%56.881.0%$1137.67m
LLYEli Lilly & Co. 0.16%141.841.1%$861.43m
NVSNovartis AG -2.18%83.860.2%$293.22m
AZNAstraZeneca Plc -2.71%43.111.2%$291.10m
GSKGlaxoSmithKline Plc -0.90%37.570.2%$251.33m
SNYSanofi -3.30%44.600.2%$169.62m
NVONovo Nordisk A/S -3.46%58.560.1%$168.58m
FTSVForty Seven, Inc. 0.05%95.510.0%$145.52m
BHCBausch Health Cos., Inc. 1.51%14.840.0%$99.58m
RGENRepligen Corp. -4.03%96.657.1%$69.48m
RETAReata Pharmaceuticals, Inc. -2.63%134.653.4%$63.83m

Company Profile

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.